Skip to main content

Table 3 The effect of pregnancy and labor on MS outcomes

From: Outcomes of pregnancy in Egyptian women with multiple sclerosis in the new treatment era: a multi-center retrospective observational study

Characteristic Total, n = 116
Pregnancy  
 Relapse during pregnancy, no. (%) 13 (11.21%)
DMT use during pregnancya, no. (%)  
 Intentionally 6 (5.17%)
 Accidentally (at first trimester) 38 (32.76%)
DMT type used (Intentionally)  
 Interferon-beta 5 (83.33%)
DMT type used (Accidentally)  
 Interferon-beta 15 (39.47%)
 Dimethyl fumarate 7 (18.42%)
 Fingolimod 12 (31.58%)
 Rituximab 3 (7.89%)
 ocrelizumab 1 (2.63%)
Postpartum period  
 No. of pregnancies with postpartum relapses, no. (%)  
  0 85 (73.28%)
  1 24 (20.69%)
  2 5 (4.31%)
  ≥ 3 2 (1.72%)
Time to first postpartum relapseb, median (IQR), days 171 (78–232)
DMT use during postpartum year, no. (%)  
 None 69 (59.48%)
 Interferon-beta 22 (18.97%)
 Dimethyl fumarate 7 (6.03%)
 Natalizumab 3 (2.57%)
 Rituximab 4 (3.45)
 Fingolimod 8 (6.90%)
 Ocrelizumab 3 (2.57%)
 Time to restart DMT after deliveryc (median, IQR), d 86 (29–201)
  1. DMT disease-modifying therapy; IQR interquartile range; MS multiple sclerosis
  2. aDuring the second and/or third trimester
  3. bOf those who relapse
  4. cOf those who resumed DMTs